Literature DB >> 12970455

Development and use of a vaccinia virus neutralization assay based on flow cytometric detection of green fluorescent protein.

Patricia L Earl1, Jeffrey L Americo, Bernard Moss.   

Abstract

A rapid and sensitive neutralization assay is required to evaluate alternative smallpox vaccines. Here we describe the development and use of a 96-well plate, semi-automated, flow cytometric assay that uses a recombinant vaccinia virus expressing enhanced green fluorescent protein and which would be applicable to other viruses.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12970455      PMCID： PMC228521          DOI： 10.1128/jvi.77.19.10684-10688.2003

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  8 in total

1.  Visualizing priming of virus-specific CD8+ T cells by infected dendritic cells in vivo.

Authors:  Christopher C Norbury; Daniela Malide; James S Gibbs; Jack R Bennink; Jonathan W Yewdell
Journal:  Nat Immunol       Date:  2002-02-04       Impact factor: 25.606

2.  Neutralizing epitope on penetration protein of vaccinia virus.

Authors:  Y Ichihashi; M Oie
Journal:  Virology       Date:  1996-06-15       Impact factor: 3.616

3.  E. coli beta-glucuronidase (GUS) as a marker for recombinant vaccinia viruses.

Authors:  M W Carroll; B Moss
Journal:  Biotechniques       Date:  1995-09       Impact factor: 1.993

Review 4.  Smallpox: a potential agent of bioterrorism.

Authors:  Richard J Whitley
Journal:  Antiviral Res       Date:  2003-01       Impact factor: 5.970

5.  General method for production and selection of infectious vaccinia virus recombinants expressing foreign genes.

Authors:  M Mackett; G L Smith; B Moss
Journal:  J Virol       Date:  1984-03       Impact factor: 5.103

6.  Green fluorescent protein expressed by a recombinant vaccinia virus permits early detection of infected cells by flow cytometry.

Authors:  J Domínguez; M M Lorenzo; R Blasco
Journal:  J Immunol Methods       Date:  1998-11-01       Impact factor: 2.303

7.  Vaccinia virus expression vector: coexpression of beta-galactosidase provides visual screening of recombinant virus plaques.

Authors:  S Chakrabarti; K Brechling; B Moss
Journal:  Mol Cell Biol       Date:  1985-12       Impact factor: 4.272

8.  Intracellular localization of proteasomal degradation of a viral antigen.

Authors:  L C Antón; U Schubert; I Bacík; M F Princiotta; P A Wearsch; J Gibbs; P M Day; C Realini; M C Rechsteiner; J R Bennink; J W Yewdell
Journal:  J Cell Biol       Date:  1999-07-12       Impact factor: 10.539
  8 in total
  55 in total

1.  A recombinant flagellin-poxvirus fusion protein vaccine elicits complement-dependent protection against respiratory challenge with vaccinia virus in mice.

Authors:  Kristen N Delaney; James P Phipps; John B Johnson; Steven B Mizel
Journal:  Viral Immunol       Date:  2010-04       Impact factor: 2.257

2.  Preexisting vaccinia virus immunity decreases SIV-specific cellular immunity but does not diminish humoral immunity and efficacy of a DNA/MVA vaccine.

Authors:  Sunil Kannanganat; Pragati Nigam; Vijayakumar Velu; Patricia L Earl; Lilin Lai; Lakshmi Chennareddi; Benton Lawson; Robert L Wilson; David C Montefiori; Pamela A Kozlowski; Bernard Moss; Harriet L Robinson; Rama Rao Amara
Journal:  J Immunol       Date:  2010-11-12       Impact factor: 5.422

3.  Vaccinia virus F9 virion membrane protein is required for entry but not virus assembly, in contrast to the related L1 protein.

Authors:  Erica Brown; Tatiana G Senkevich; Bernard Moss
Journal:  J Virol       Date:  2006-10       Impact factor: 5.103

4.  Vaccinia virus entry into cells via a low-pH-dependent endosomal pathway.

Authors:  Alan C Townsley; Andrea S Weisberg; Timothy R Wagenaar; Bernard Moss
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

5.  Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus.

Authors:  Zhaochun Chen; Patricia Earl; Jeffrey Americo; Inger Damon; Scott K Smith; Yi-Hua Zhou; Fujuan Yu; Andrew Sebrell; Suzanne Emerson; Gary Cohen; Roselyn J Eisenberg; Juraj Svitel; Peter Schuck; William Satterfield; Bernard Moss; Robert Purcell
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-25       Impact factor: 11.205

6.  Expression of the A56 and K2 proteins is sufficient to inhibit vaccinia virus entry and cell fusion.

Authors:  Timothy R Wagenaar; Bernard Moss
Journal:  J Virol       Date:  2008-11-26       Impact factor: 5.103

7.  Evaluation of monkeypox disease progression by molecular imaging.

Authors:  Julie Dyall; Reed F Johnson; Dar-Yeong Chen; Louis Huzella; Dan R Ragland; Daniel J Mollura; Russell Byrum; Richard C Reba; Gerald Jennings; Peter B Jahrling; Joseph E Blaney; Jason Paragas
Journal:  J Infect Dis       Date:  2011-10-19       Impact factor: 5.226

8.  Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.

Authors:  Linda S Wyatt; Patricia L Earl; Leigh Anne Eller; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-11       Impact factor: 11.205

9.  Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus.

Authors:  Patricia L Earl; Jeffrey L Americo; Linda S Wyatt; Ondraya Espenshade; Jocelyn Bassler; Kathy Gong; Shuling Lin; Elizabeth Peters; Lowrey Rhodes; Yvette Edghill Spano; Peter M Silvera; Bernard Moss
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-04       Impact factor: 11.205

10.  Engineering the vaccinia virus L1 protein for increased neutralizing antibody response after DNA immunization.

Authors:  Kaori Shinoda; Linda S Wyatt; Kari R Irvine; Bernard Moss
Journal:  Virol J       Date:  2009-03-03       Impact factor: 4.099
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.